BioPharmSignal logoBioPharmSignal

Biotech News

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics (IKT)Inhibikase Therapeutics2026-04-07 12:00 ESTClinical readout

IKT (IKT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ikt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IKTInhibikase Therapeutics2026-05-12 20:01 EST

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

IKTInhibikase Therapeutics2026-04-03 18:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IKTInhibikase Therapeutics2026-03-26 20:01 EST

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

IKTInhibikase Therapeutics2025-11-21 02:54 EST

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

IKTInhibikase Therapeutics2025-11-20 21:12 EST

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IKTInhibikase Therapeutics2025-11-20 21:01 EST

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

IKTInhibikase Therapeutics2025-11-14 21:01 EST

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

View all latest news

Inhibikase Therapeutics

Inhibikase Therapeutics is a clinical-stage biotech focused on kinase inhibition and neurologic or oncology-related indications. Its story is centered on developing small-molecule therapies that can be differentiated by mechanism and tolerability.

Recent company news

IKTBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

IKTQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

IKTMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

IKTAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

Stock data

Close
2.33 USD
Market cap
224.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States